<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Projects | Li Rui - Shanghaitech University</title>
    <link>https://example.com/project/</link>
      <atom:link href="https://example.com/project/index.xml" rel="self" type="application/rss+xml" />
    <description>Projects</description>
    <generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Sun, 16 Mar 2025 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://example.com/media/icon_hub68f9f726768a10afc6f12769d72c9cc_64789_512x512_fill_lanczos_center_3.png</url>
      <title>Projects</title>
      <link>https://example.com/project/</link>
    </image>
    
    <item>
      <title>Gout Biomarkers</title>
      <link>https://example.com/project/gout-biomarker/</link>
      <pubDate>Sun, 16 Mar 2025 00:00:00 +0000</pubDate>
      <guid>https://example.com/project/gout-biomarker/</guid>
      <description>&lt;p&gt;To discover differential metabolites and pathways underlying infrequent gout flares (InGF) and frequent gout flares (FrGF) using metabolomics and establish a predictive model by machine learning (ML) algorithms.&lt;/p&gt;
&lt;p&gt;Serum samples from a discovery cohort with 163 InGF and 239 FrGF patients were analyzed by mass spectrometry-based untargeted metabolomics to profile differential metabolites and explore dysregulated metabolic pathways using pathway enrichment analysis and network propagation-based algorithms. ML algorithms were performed to establish a predictive model based on selected metabolites, which was further optimized by a quantitative targeted metabolomics method and validated in an independent validation cohort with 97 participants with InGF and 139 participants with FrGF.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;&#34; srcset=&#34;
               /project/gout-biomarker/featured_hu5ff4b702542ee11d8f4ec2e442845abc_469209_a6b0d322271a1e5271f5fec209ccd37c.webp 400w,
               /project/gout-biomarker/featured_hu5ff4b702542ee11d8f4ec2e442845abc_469209_bfb8102bc82ad550c8f8e3597cca9e2f.webp 760w,
               /project/gout-biomarker/featured_hu5ff4b702542ee11d8f4ec2e442845abc_469209_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;https://example.com/project/gout-biomarker/featured_hu5ff4b702542ee11d8f4ec2e442845abc_469209_a6b0d322271a1e5271f5fec209ccd37c.webp&#34;
               width=&#34;760&#34;
               height=&#34;450&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;Differential metabolites between InGF and FrGF groups were identified.
Top dysregulated pathways included carbohydrates, amino acids, bile acids, and nucleotide metabolism.
















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;&#34; srcset=&#34;
               /project/gout-biomarker/profile_hu764eca2bd43ad301033b8004d65fa004_768991_7a2dbd02bdf2600349a78e70c0d8369b.webp 400w,
               /project/gout-biomarker/profile_hu764eca2bd43ad301033b8004d65fa004_768991_2ee16e4a62d1594d1c93531fa82f8477.webp 760w,
               /project/gout-biomarker/profile_hu764eca2bd43ad301033b8004d65fa004_768991_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;https://example.com/project/gout-biomarker/profile_hu764eca2bd43ad301033b8004d65fa004_768991_7a2dbd02bdf2600349a78e70c0d8369b.webp&#34;
               width=&#34;760&#34;
               height=&#34;493&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;Subnetworks with maximum disturbances in the global metabolic networks featured cross-talk between purine metabolism and
caffeine metabolism, as well as interactions among pathways involving primary bile acid biosynthesis,
taurine and hypotaurine metabolism, alanine, aspartate and glutamate metabolism, suggesting epigenetic
modifications and gut microbiome in metabolic alterations underlying InGF and FrGF.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;&#34; srcset=&#34;
               /project/gout-biomarker/network_hub544bbb1f37149713d8f03b3cdabf7b3_274748_442fcc24b87de2801704dabb2b3b516f.webp 400w,
               /project/gout-biomarker/network_hub544bbb1f37149713d8f03b3cdabf7b3_274748_52ca9085a0fc2be48fa6b782a31561b7.webp 760w,
               /project/gout-biomarker/network_hub544bbb1f37149713d8f03b3cdabf7b3_274748_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;https://example.com/project/gout-biomarker/network_hub544bbb1f37149713d8f03b3cdabf7b3_274748_442fcc24b87de2801704dabb2b3b516f.webp&#34;
               width=&#34;760&#34;
               height=&#34;685&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;Potential metabolite biomarkers were identified using ML-based multivariable selection and further
validated by targeted metabolomics. Area under receiver operating characteristics curve for
differentiating InGF and FrGF achieved 0.88 and 0.67 for the discovery and validation cohorts, respectively.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;&#34; srcset=&#34;
               /project/gout-biomarker/prediction_hufe0dcbc2597f702e77573a29848268e2_109614_1550b8ce0f9386b70b6ce2fa93b5dbe9.webp 400w,
               /project/gout-biomarker/prediction_hufe0dcbc2597f702e77573a29848268e2_109614_fb9ba3f0b2fc2e4ed3a1f0c6fb8eb4fa.webp 760w,
               /project/gout-biomarker/prediction_hufe0dcbc2597f702e77573a29848268e2_109614_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;https://example.com/project/gout-biomarker/prediction_hufe0dcbc2597f702e77573a29848268e2_109614_1550b8ce0f9386b70b6ce2fa93b5dbe9.webp&#34;
               width=&#34;760&#34;
               height=&#34;319&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
&lt;p&gt;In summary, Systematic metabolic alterations underlie InGF and FrGF, and distinct profiles are associated with differences in gout flare frequencies. Predictive modeling based on selected metabolites from metabolomics can differentiate InGF and FrGF.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Mass Spectrometry based Isotopomer Parsing</title>
      <link>https://example.com/project/msip/</link>
      <pubDate>Wed, 27 Apr 2016 00:00:00 +0000</pubDate>
      <guid>https://example.com/project/msip/</guid>
      <description></description>
    </item>
    
    <item>
      <title>MSdev</title>
      <link>https://example.com/project/msdev/</link>
      <pubDate>Wed, 27 Apr 2016 00:00:00 +0000</pubDate>
      <guid>https://example.com/project/msdev/</guid>
      <description>&lt;p&gt;The lack of a universal analytical platform is one of the key factors
limiting the biological application and development of metabolomics methodologies.
We developed a metabolomics data analysis and method development platform, MSdev.
MSdev integrates and develops various core tools and databases, including mass spectrometry
data analysis, chemical computations, metabolomics databases, and molecular graph structures.
This platform not only facilitates our routine metabolomics and metabolic flux analysis but also supports the development of advanced methods such as MSIP and MFNA.&lt;/p&gt;
&lt;p&gt;















&lt;figure  &gt;
  &lt;div class=&#34;d-flex justify-content-center&#34;&gt;
    &lt;div class=&#34;w-100&#34; &gt;&lt;img alt=&#34;&#34; srcset=&#34;
               /project/msdev/MSdev_structure_hua35508d5c6e5200ce0ca0133367b0f29_273571_4d9a19f6977d55e72357d649563a192b.webp 400w,
               /project/msdev/MSdev_structure_hua35508d5c6e5200ce0ca0133367b0f29_273571_06e41033b09926f68718095b061a53f8.webp 760w,
               /project/msdev/MSdev_structure_hua35508d5c6e5200ce0ca0133367b0f29_273571_1200x1200_fit_q75_h2_lanczos_3.webp 1200w&#34;
               src=&#34;https://example.com/project/msdev/MSdev_structure_hua35508d5c6e5200ce0ca0133367b0f29_273571_4d9a19f6977d55e72357d649563a192b.webp&#34;
               width=&#34;760&#34;
               height=&#34;547&#34;
               loading=&#34;lazy&#34; data-zoomable /&gt;&lt;/div&gt;
  &lt;/div&gt;&lt;/figure&gt;
&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
